Glenmark Pharmaceuticals ' biotech arm, Ichnos Glenmark Innovation (IGI), has introduced ISB 2301, a first-in-class, multispecific immune cells activator designed for the potential treatment of multiple solid tumor indications. The announcement marks a significant advancement in the venture's oncology pipeline, leveraging its proprietary BEAT® technology platform to address the biological complexity of solid tumors.

ISB 2301: A Multispecific Immune Cells Activator

ISB 2301 is a next-generation multispecific antibody that targets three tumor-associated antigens to trigger tumor cell death. It engages both T cells and natural killer (NK) cells to ignite the immune system, offering a multi-mechanistic approach to cancer treatment. The candidate is classified as a first-in-class molecule, designed to induce potent antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition, and a sustained type 1 immune response.

Strategic Development and Clinical Plans

The development of ISB 2301 was enabled by IGI's clinically validated BEAT® platform, which allows for manufacturing with a standard multispecific antibody process. Preclinical data indicates that ISB 2301 demonstrates excellent pharmacokinetics, tolerability, and a favorable safety profile in non-human primates. Building on the platform's success, IGI intends to submit an Investigational New Drug (IND) application for ISB 2301 by the end of this year, with clinical studies scheduled to begin in 2027.

Glenmark Pharmaceuticals Inc., USA announced on May 18, 2026, the launch of Vancomycin Hydrochloride for Injection USP in two strengths — 500 mg/vial and 1 g/vial — from its base in Elmwood Park, New Jersey. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial, of Fresenius Kabi USA, LLC. This launch further expands the company's injectable portfolio in the United States market.

Product and Market Overview

The newly launched product enters a market that has demonstrated notable commercial scale. According to IQVIA® National Sales Perspectives: Retail & Non-Retail data for the 12-month period ending March 2026, the Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial market achieved annual sales of approximately $37.9 million. The market figure includes the brand and all available therapeutic equivalents.

Key details of the product launch are summarised below:

Leadership Commentary

Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, "The launch of Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial reflects Glenmark's continued commitment to expanding access to quality, affordable medicines in the U.S. It also strengthens our injectable portfolio and reinforces our focus on delivering reliable treatment options to healthcare providers and patients."

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd. is a global, research-led pharmaceutical company with a focus on innovation and accessibility. The company operates 11 manufacturing facilities across four continents, supported by six R&D centres, and maintains a commercial presence in 80+ countries. Its diversified portfolio spans branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024.

Note: Glenmark's Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial is approved only for the indication(s) listed in Glenmark's approved label. IQVIA® data obtained by Glenmark is only available for all approved RLD indications; Glenmark's product is only approved for the indications listed in its approved label and is not marketed for all RLD indications.